<DOC>
	<DOCNO>NCT00887029</DOCNO>
	<brief_summary>Hypothesis : - H1 : Efficacy Duotrav superior Xalacom 24 hour post dose medication give morning - H2 : A significant proportion patient prefer dose daily topical fix combination therapy morning compare evening dose</brief_summary>
	<brief_title>A 12 Week Comparison DuoTrav Xalacom Open-Angle Glaucoma</brief_title>
	<detailed_description>- Primary objective : Compare IOP-lowering efficacy morning dose Duotrav Xalacom . - Secondary objective : Compare patient dose preference topical prostaglandin therapy term convenience perceive compliance .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients ≥ 18 year old , diagnose primary open angle glaucoma ocular hypertension IOP currently uncontrolled beta blocker monotherapy , judge investigator Response Timolol 0.5 % ≥10 % reduction IOP IOP 9:00 ≥ 20 mmHg still beta blocker Nonprescription prescription topical ophthalmic product systemic medication mention exclusion criterion allow study . Patients wear contact lens permit participate study provide contact lens remove instillation study medication patient wait fifteen ( 15 ) minute follow drug instillation reinsert lens . Contact lenses worn study day . Best correct visual acuity bad 0.6 logMAR 20/80 Snellen either eye . Patients mean IOP either eye screening exam visit great 36 mmHg History ocular trauma within past six ( 6 ) month . History ocular infection ocular inflammation within past three ( 3 ) month . History chronic recurrent severe inflammatory eye disease ( i.e. , scleritis , uveitis ) History severe serious hypersensitivity component study medication . Any abnormality prevent reliable applanation tonometry either eye . Intraocular surgery within past six ( 6 ) month determine patient history and/or examination . Patients cup/disc ratio great 0.80 either eye . Patients severe central visual field loss either eye define sensitivity 10 dB least two ( 2 ) four ( 4 ) visual field test point closest point fixation . History severe retinal disease retinal degeneration , diabetic retinopathy retinal detachment . Current use ANY glucocorticoid administer route . Patient must wash glucocorticoid least 4 week prior study entry . Use systemic prostaglandin prostaglandin analogue ( e.g. , CYTOTEC ) within last three month . Current use topical nonsteroidal anti inflammatory agent inhibit cyclooxygenase prostaglandin analogue synthesis . Any form glaucoma openangle glaucoma ( without pigment dispersion pseudoexfoliation component ) . Current use topical nonsteroidal anti inflammatory agent inhibit cyclooxygenase prostaglandin analogue synthesis Angle grade le 2 ( extreme narrow angle complete partial closure ) measure gonioscopy . Therapy another investigational agent within past 30 day Patients would risk treatment topical prostaglandin prostaglandin analogue , contraindicate use betablockers medication use study , would risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Topical prostaglandin analogue</keyword>
	<keyword>glaucoma</keyword>
	<keyword>POAG</keyword>
	<keyword>OHT</keyword>
	<keyword>OAG</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>fix combination protaglandin analogue therapy</keyword>
	<keyword>DuoTrav</keyword>
	<keyword>timolol</keyword>
	<keyword>travoprost</keyword>
	<keyword>24 hour post dose</keyword>
	<keyword>IOP</keyword>
	<keyword>dose preference</keyword>
</DOC>